Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers
Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers
This study will enroll 200 men with clinical suspicion of prostate cancer due to higher serum
 level of PSA than 2.5 ng/ml or abnormal digital rectal examination.

 Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) at 3 Tesla
 (T) magnetic field using surface coils will be used to non-invasively predict the presence or
 absence of prostate cancer.

 Targeted TRUS guided biopsy based on MRI findings will be performed in addition to routine
 twelve core TRUS biopsy.

 Moreover, selected serum and urine biomarkers as well as biomarkers extracted from fresh
 biopsy sample will be collected and correlated with the presence or absence of prostate
 cancer.
Specific aims of the current study are as follows:

 i) To determine the sensitivity, specificity and accuracy of a novel rapid anatomical MRI and
 DWI at 3T magnetic field for the detection of prostate cancer in correlation with systematic
 TRUS guided biopsy

 ii) To determine the sensitivity, specificity and accuracy of selected serum, urine and
 tissue biomarkers for detection of prostate cancer

 iii) To develop statistical model for diagnosis of prostate cancer incorporating findings of
 a novel rapid MRI/DWI and selected biomarkers

 iv) To assess the applicability of TRUS guided prostate biopsy based on MRI finding in
 patient with no previous prostate biopsy

 v) To develop and validate an imaging protocol which will become the standard protocol for
 prostate imaging at Medical Imaging Centre of Southwest Finland (VSKK) / TYKS, Turku,
 Finland.
Inclusion Criteria:

 -  Age: 40 to 85 years

 -  Language spoken: Finnish

 -  Clinical suspicion of prostate cancer, based on: serum level of PSA from 2,5 ng/ml to
 25 ng/ml in two following measurements and/or abnormal digital rectal examination

 -  Mental status: Patients must be able to understand the meaning of the study

 -  Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved
 informed consent documents in the presence of the designated staff

 Exclusion Criteria:

 -  previous prostate biopsies

 -  previous diagnosis of prostate carcinoma

 -  previous prostate surgeries, e.g. TURP (transurethral prostatic resection)

 -  symptomatic of acute prostatitis

 -  contraindications for MRI (cardiac pacemaker, intracranial clips etc)

 -  uncontrolled serious infection

 -  claustrophobia

 -  any other conditions that might compromise patients safety, based on the clinical
 judgment of the responsible urologist